United States securities and exchange commission logo
September 23, 2020
Milton H. Werner
President and Chief Executive Officer
Inhibikase Therapeutics, Inc.
3350 Riverwood Parkway SE, Suite 1927
Atlanta, GA 30339
Re: Inhibikase
Therapeutics, Inc.
Amendment No. 1 to
Registration Statement on Form S-1
Filed September 15,
2020
File No. 333-240036
Dear Dr. Werner:
We have reviewed your amended registration statement and have the
following
comments. In some of our comments, we may ask you to provide us with
information so we
may better understand your disclosure.
Please respond to this letter by amending your registration
statement and providing the
requested information. If you do not believe our comments apply to your
facts and
circumstances or do not believe an amendment is appropriate, please tell
us why in your
response.
After reviewing any amendment to your registration statement and
the information you
provide in response to these comments, we may have additional comments.
Unless we note
otherwise, our references to prior comments are to comments in our
August 14, 2020 letter.
Amendment No. 1 to Form S-1 filed September 15, 2020
Inside Cover Page, page i
1. We note your response
to comment 2, and expanded disclosure regarding the nature of
Dementia with Lewy
Body and animal studies for Multiple System Atrophy and
Progressive Multifocal
Leukoencephalopathy. Please provide further support for you
belief that your
research program for Dementia with Lewy Body is material as it currently
appears you have not
begun research in this area. Additionally, revise your business
section to describe the
material terms of your collaborative arrangements with Rush
University and
Louisiana State University. Please file these agreements as exhibits or
provide us with an
analysis supporting your determination that you are not dependent on
them.
Milton H. Werner
Inhibikase Therapeutics, Inc.
September 23, 2020
Page 2
Prospectus Summary
Overview, page 1
2. We note your response to comment 5; however, the statement, "We believe
IkT-001Pro
will improve patient experience and treatment compliance and could
become the standard-
of-care as a result" remains on page 95. Please revise to eliminate the
implication that
your product will be effective.
Management s Discussion and Analysis of Financial Condition and Results of
Operations
Critical Accounting Policies and Significant Judgments and Estimates
Stock-Based Compensation, page 92
3. Please revise your disclosure to quantify the stock compensation expense
for both of the
warrants issued August 25, 2020 in the aggregate as well as the amount
that will be
recognized in your September 30, 2020 financial statements.
You may contact Rolf Sundwall at (202) 551-3105 or Sasha Parikh at (202)
551-3627 if
you have questions regarding comments on the financial statements and related
matters. Please
contact Abby Adams at (202) 551-6902 or Suzanne Hayes at (202) 551-3675 with
any other
questions.
Sincerely,
FirstName LastNameMilton H. Werner
Division of
Corporation Finance
Comapany NameInhibikase Therapeutics, Inc.
Office of Life
Sciences
September 23, 2020 Page 2
cc: Merrill M. Kraines, Esq.
FirstName LastName